Eli Lilly — Aug 7, 2025 release

2025 Guidance Earnings per share (reported) $20.85 to $22.10 U.S. tax legislation .38 Amortization of intangible assets .42 Asset impairment, restructuring, and other special charges .03 Net losses on investments in equity securities .05 Earnings per share (non-GAAP) $21.75 to $23.00 Numbers may not add due to rounding 2 The Company defines performance margin as gross margin less R&D, Marketing, Selling, and Administrative and Asset Impairment, Restructuring and Other Charges divided by Revenue. 7 The following table summarizes the company's updated 2025 financial guidance: Prior Updated (1) (2) (3) Revenue $58.0 to $61.0 billion $60.0 to $62.0 billion Performance Margin (4) (reported) 40.5% to 42.5% 42.0% to 43.5% (non-GAAP) 41.5% to 43.5% 43.0% to 44.5% Other Income/(Expense) (reported) ($850) to ($750) million ($750) to ($650) million Other Income/(Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate (reported) Approx. 17% Approx. 19% Tax Rate (non-GAAP) Approx. 17% Unchanged Earnings per Share (reported) $20.17 to $21.67 $20.85 to $22.10 Earnings per Share (non-GAAP) $20.78 to $22.28 $21.75 to $23.00 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) Guidance includes acquired IPR&D charges through Q2 2025 of $1.73 billion or $1.86 on a per share basis. Guidance does not include acquired IPR&D either incurred, or expected to be incurred, after Q2 2025. (3) This guidance is based on the